HRG-mediated activation of HER3 leads to downstream PI3K/AKT pathway signaling, promoting cell survival, and imparting resistance to EGFR-targeted therapies, a cornerstone of the NSCLC treatment (39, 40). This evidence concerns the gene EGFR and non-small cell lung carcinoma.